Boston Scientific vs Takeda Pharmaceutical
Boston Scientific (BSX), health care, and Takeda Pharmaceutical (TAK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Takeda Pharmaceutical is worth $69.3B on the stock market and Boston Scientific $62.6B: Takeda Pharmaceutical is valued at 11% more. Boston Scientific trades at 18.2 times earnings and Takeda Pharmaceutical at 310; operating margins in their latest fiscal years were 18.0% and 0.14%. Over the past year Boston Scientific's share price has moved -56.0% and Takeda Pharmaceutical's +53.4%.
Key facts
- Boston Scientific market value
- $62.6B
- Takeda Pharmaceutical market value
- $69.3B
- Boston Scientific P/E
- 18.2
- Takeda Pharmaceutical P/E
- 310
- Boston Scientific revenue
- $20.1BFY to 2025-12-31
- Takeda Pharmaceutical revenue
- $28.2BFY to 2026-03-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Boston Scientific | Takeda Pharmaceutical |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size | ||
| Market cap | $62.6Blower | $69.3Bhigher |
| Revenue | $20.1Blower | $28.2Bhigher |
| Earnings | $2.9Bhigher | -$954.4Mlower |
| Employees | 59,000higher | 47,029lower |
| Total assets | $43.7Blower | $97.1Bhigher |
| Valuation | ||
| P/E | 18.2lower | 310higher |
| P/S | 3.1higher | 2.5lower |
| P/B | 2.4 | — |
| Dividend yield | 0.00% | — |
| Profitability | ||
| Operating margin | 18.0%higher | 0.14%lower |
| Balance sheet | ||
| Net assets | $24.2Blower | $46.5Bhigher |
| Total liabilities | $19.2Blower | $50.6Bhigher |
| Total debt | $11.4Blower | $30.6Bhigher |
| Cash on hand | $2Blower | $3.7Bhigher |
| Price change | ||
| Today | -1.09%lower | +0.46%higher |
| 1 year | -56.0%lower | +53.4%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Boston Scientific only (13)
- Andrew Spokes2.6%
- Lee Ainslie2.3%
- Primecap team1.6%
- Steven Romick1.2%
- Louis Bacon0.8%
- David Shaw (founder)0.7%
- John Overdeck and David Siegel (founders)0.6%
- Sarah Ketterer0.4%
- Dodge & Cox team0.3%
- Temasek0.3%
- Paul Tudor Jones0.3%
- Israel Englander0.1%
- Larry Robbins0.1%
Takeda Pharmaceutical only (2)
Percentages are each holding's share of that investor's reported portfolio. Who owns BSX · Who owns TAK
More on Boston Scientific
Further comparisons
Boston Scientific against its closest peers
Takeda Pharmaceutical against its closest peers
Learn
Questions and answers
Which is bigger, Boston Scientific or Takeda Pharmaceutical?
By market value, Takeda Pharmaceutical is the larger: $69.3B against $62.6B for Boston Scientific. By revenue in its latest fiscal year, Takeda Pharmaceutical is the larger: $28.2B against $20.1B for Boston Scientific.
Which has the higher P/E ratio?
Takeda Pharmaceutical: 310, against 18.2 for Boston Scientific. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Boston Scientific: 18.0%, against 0.14% for Takeda Pharmaceutical. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Takeda Pharmaceutical: $30.6B, against $11.4B for Boston Scientific. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Boston Scientific and Takeda Pharmaceutical?
None of the tracked superinvestors holds both in their latest 13F filing. 13 hold Boston Scientific and 2 hold Takeda Pharmaceutical.
Cite this page
Funkfolio, “Boston Scientific vs Takeda Pharmaceutical”, data as of 17 November 2026. https://funkfolio.com/compare/bsx-vs-tak
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.